Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

83.86 -0.97 (-1.15%)
Streaming Delayed Price Updated: 3:41 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
72 73 Next >
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology
Via CannabisNewsWire
Topics Intellectual Property
Royal Rule: Buy These 3 Dividend Aristocrats on Every. Single. Dip.
Choosing dividend aristocrats to buy becomes easy when you elect to buy the royalty of income-generating stocks. 
Via InvestorPlace
Investigating AstraZeneca's Standing In Pharmaceuticals Industry Compared To Competitors
 
Via Benzinga
Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal
Eccogene, a Shanghai-Boston biotech, out-licensed global rights (ex-China) for its novel small molecule GLP-1 agonist to AstraZeneca in a $2 billion blockbuster deal. Eccogene will receive $185 million... 
Via Talk Markets
The 7 Next Trillion Dollar Companies to Invest in to Become a Millionaire
These are the next trillion-dollar companies to buy as they represent strong business fundamentals with robust cash flow upside potential. 
Via InvestorPlace
Price Over Earnings Overview: AstraZeneca
 
Via Benzinga
Comparative Study: AstraZeneca And Industry Competitors In Pharmaceuticals Industry
 
Via Benzinga
AstraZeneca Plc (AZN) Q3 2023 Earnings Call Transcript
AZN earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Auto Trader & AstraZeneca Help FTSE Reverse Early Losses
As the day progressed, the initial downturn was reversed, and the blue-chip index managed to secure gains just shy of 1%. 
Via Talk Markets
AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs
The company is licensing a new GLP-1 drug in the hopes of taking on Novo and Lilly. 
Via Investor's Business Daily
AstraZeneca Joins Anti-Obesity Race Dominated By Eli Lilly And Novo Nordisk, Reports Mixed Q3 Earnings
AstraZeneca Plc (NASDAQ: AZN) has reported Q3 FY23 core EPS of $1.73, u 
Via Benzinga
Wall Street To Snap Longest Winning Streak Since 2021 Today? Earnings, Bond Yields In Focus Ahead Of Powell's Speech
The stock market’s momentum appears to be waning, and futures suggest a mixed opening for Thursday. Earnings reports have generally been positive, with companies like Walt Disney Co. 
Via Benzinga
Earnings Review: AstraZeneca Increases Profit Outlook, Reports 17% EPS Growth
AstraZeneca reported an EPS of $1.73 for Q3 2023 and $5.8 for 9M 2023. 
Via Talk Markets
IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial
From AstraZeneca
Via Business Wire
AstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivity
From AstraZeneca
Via Business Wire
BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake
The company's recently FDA-approved gene therapy is struggling to gain traction. 
Via Investor's Business Daily
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Impact of Exclusive Drug-Delivery Solution on GLP-1 Drugs
Via Investor Brand Network
Topics Intellectual Property
Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial
From AstraZeneca
Via Business Wire
7 Evergreen Stocks for Long-term Wealth Generation
These are the stocks to buy for long-term wealth as they represent companies that will continue to grow and boost shareholder returns. 
Via InvestorPlace
Why Is Cancer Player Cellectis Stock Trading Over 100% Higher Today?
Cellectis SA (NASDAQ: CLLS) shares are trading higher after the company  
Via Benzinga
Why Is Cellectis (CLLS) Stock Up 175% Today?
Cellectis stock is taking off on Wednesday as investors in CLLS react to a massive $245 million investment from AstraZeneca. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today! 
Via InvestorPlace
Can Diabetes, Weight-Loss Drugs Get Even Better?
Via Investor Brand Network
Can Diabetes, Weight-Loss Drugs Get Even Better?
EQNX::TICKER_START (NASDAQ:LEXX,NYSE:NVO:NYSE:PFE,NYSE:MRK,NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
3 No-Brainer Stocks to Buy for Under $100 Right Now
A couple of these stocks might not be available for under $100 for too much longer. 
Via The Motley Fool
Why Is LumiraDx (LMDX) Stock Down 35% Today?
LumiraDx stock is falling on Tuesday as shares of LMDX stock give up some of the gains they saw on Monday after announcing a partnership. 
Via InvestorPlace
US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal)
From AstraZeneca
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
From AstraZeneca
Via Business Wire
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.